Repligen secured fast-track designation from the FDA for a treatment candidate for spinal muscular atrophy, a genetic neurodegenerative disorder. The drug has orphan-drug status in the EU.
Published in Brief:
|Vice President of Regulatory Affairs||
|Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX||
|Santa Clara, CA|
|Senior Director, Biostatistics||